Overview

Magnitude is a leading provider of data management solutions to enable organisations and business users to more effectively access, extract and analyse data from various ERP, cloud-applications, and other IT systems.  The company is headquartered in Austin, Texas, with global operations in the US, Canada, the Netherlands, UK and India. It has over 1,400 customers, including 50% of the Fortune 100.

The company has a portfolio of best-in-class products to unify fragmented data and deliver actionable insights for critical business decisions.  A few example applications include:

• an analytics tools to enable a business analyst to extract and harmonize data from SAP ERP to provide real-time, actionable insights on bottlenecks in the supply chain,
• a data integration tool to pull data from dispersed data systems sources into SAP Central Finance to enable a large enterprise to see all of their financial data in one place,
• a connectivity driver to enable different applications that companies use (such as Marketto, Salesforce, or Cloudera) to connect to one-another. 

3i invested in Magnitude in May 2019 and will look to accelerate the company’s global growth ambitions through new product development, investments in sales & marketing, and additional M&A. 

Highlights

• Growth tailwinds driven by the proliferation of data and increasing complexity of the enterprise software suit
• Focus on innovation and new product development, with a number of recent new product launches
• Buy-and-build platform with three acquisitions completed in the last 18 months
• Global sales presence with more than a third of sales into Europe

Regulatory information 
This transaction involved a recommendation of 3i Corporation, a US wholly owned subsidiary of 3i Group.

Overview

Q Holding is a leading global manufacturer of highly-engineered, fully assembled medical devices and precision-molded elastomeric components used in a broad range of Life Sciences (medical and pharmaceutical) and Electrical Management (industrial, automotive and aerospace) applications. Headquartered in Ohio, it sells products in over 50 countries and has 13 manufacturing locations in North America, EMEA and Asia.

Q Holding has built a strong reputation as the supplier of choice to provide high-quality mission critical components for medical and harsh environment applications. It has developed longstanding relationships with a broad range of blue-chip customers who value Q’s ability to design and develop customized solutions and manufacture globally.

Highlights

• Acquisitions of Degania Medical (Dec. 2016), a leading global manufacturer of catheters and other medical devices and Silicone Altimex (July 2015), a silicone provider of medical device components and pharmaceutical assemblies
• Strong organic growth driven by favorable trends in medical (preference for minimally invasive therapies) and industrial / auto (content growth, connectivity, IoT) end markets
• Global manufacturing footprint aligned with customers. New facilities in Mexico, supporting investments in Europe, China and India
• Experienced management team with longstanding track record of driving innovation in product and service offering

Regulatory information 
Regulatory information: This transaction involved a recommendation of 3i Corporation, a US wholly owned subsidiary of 3i Group.

Overview

Royal Sanders is a leading European private label and contract manufacturing producer of personal care products. Its key geographies are the Benelux, Germany, France and the UK with plants in the Netherlands (Vlijmen), the UK (Preston and Bradford) and Belgium (Ieper).

Main product categories include shampoo, bath and shower gels, body lotions and hand wash. The company sells its products through private label, contract manufacturing and own brands including Van Gils, Sanicur and Odorex.

3i is investing alongside management to drive the company’s international growth strategy.

Highlights 

• Demonstrated a consistent and strong track record of profitable organic growth over the past 10 years, significantly outgrowing the market
• Differentiates itself through its focus on quality and service, longstanding relationships with key customers and superior operational capabilities at its state-of-the-art facilities
• Ready to drive consolidation in a fragmented industry with multiple potential buy-and-build opportunities across geographies

Regulatory information 
This transaction involved a recommendation of 3i Investments plc, advised by 3i Benelux.

Overview

3i has established a scaled, global, pure-play platform in the bioprocessing market by bringing together SaniSure, Cellon, TBL, and Silicone Altimex (together, “SaniSure”). SaniSure is a vertically-integrated player in the single-use bioprocessing technology (“SUT“) space capable of providing highly customised and innovative solutions to leading biopharma and biotech customers. The SUT bioprocessing market is anticipated to grow at 13-20%+ across its various subsegments over the coming years, as the industry transitions to more flexible, clean, and operating cost advantaged technology relative to traditional multi-use counterparts.

Recognising an attractive market opportunity characterised by high growth and a need for a leading independent platform of scale, 3i began a journey to create a single use bioprocessing platform in January 2020 with the carve-out of Silicone Altimex from 3i portfolio company, Q Holding, along with the acquisitions of founder-owned businesses TBL and Cellon. 

Seven months later, in July 2020, the platform completed the transformative acquisition of founder-owned Sani-Tech West Inc. (Sani-Tech West and subsidiaries SaniSure® and SureTech), a leading US-based manufacturer, distributor and integrator of single-use bioprocessing systems and components. The acquisition significantly expanded the combined group’s global footprint and brought a complementary portfolio of innovative products and single-use solutions capabilities. The combined platform has robust manufacturing and cleanroom assembly operations in both North America and Europe, offering enhanced supply chain assurance to its customers with a global footprint and vertically integrated capabilities. 

Highlights

• Created a unified, vertically-integrated platform in the high-growth bioprocessing space by bringing together Cellon, TBL, and Silicone Altimex 
• Recruited key management members to complement the founders and other existing leaders, while professionalising the organisation and codifying business strategy
• Brought Sani-Tech West into the platform, doubling the size of the combined business and creating a global leader with well-established operations and reach in North America and Europe
• Positioned the platform to be a global strategic SUT solutions partner of choice for leading biopharma and biotech companies and CDMOs

Overview

Weener Plastics (“WP”) is a leading manufacturer of innovative plastic packaging systems for fast moving consumer goods companies. WP supplies the world’s leading A-brands and private label players. WP focuses on the design, development and manufacturing of value added caps, valve closures and roll-on balls for the personal care, food and beverage, and home care market.

We invested in WP in June 2015 and are supporting management to secure further sustainable growth using the existing innovation-led platform, investing in its successful international expansion strategy and continuing its operational improvement initiatives.

Highlights

• Using our international network, experience and capital to support WP’s growth through their buy-and-build strategy to expand into adjacent product categories and new geographies. WP acquired Proenfar, a leading Colombian plastic packaging manufacturer for the personal care and pharma end markets, in 2018
• Customer portfolio includes Beiersdorf, Colgate-Palmolive, L’Oréal, Nestlé, P&G, Unilever and Homann
• Excellent track record of growth
• Introduced Niall Wall, former CEO of Ardagh as Chairman as well as Laurent Philippe, former president CEEMEA of P&G, and Knut Michelberger to the Supervisory Board as Non-Executive Directors via our Business Leaders Network

Regulatory information 
This transaction involved a recommendation of 3i Investments plc, advised by 3i Germany.